ACTRN12608000208303进行中（未招募）2 期
A multi-centre, randomised, double blind, placebo-controlled, parallel group, phase IIa clinical trial to assess the efficacy and safety of Cpn10 administered as twice weekly subcutaneous injections in subjects with Rheumatoid Arthritis
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- CBio Limited
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •1. Diagnosis of RA according to the American College of Rheumatology with
- •RA Functional Class I-III.
- •2. Diagnosed at least 6 months prior to screening.
- •3. Failed at least one disease modifying anti-rheumatic drug (DMARD), but not more than five.
- •4. Taking methotrexate for at least 3 months prior to screening and at a stable maximum tolerated dose for at least 1 month prior to screening.
- •5. Any other DMARD (if taken) must have been taken for at least 3 months and be taken at a stable dose for at least one month prior to screening.
- •6. Active RA despite stable methotrexate at a maximum tolerated dose. Active RA defined as a DAS28>3.2 and at least 6 tender and swollen joints of 68 examined and either an ESR>25mm/hr or a CRP>10mg/mL.
- •7. weight <120kg.
- •8. Prednisolone (or equivalent) (if taken) must be at a dose of no more than 10 mg/ day and stable for at least one month prior to screening.
- •9. Non-steroidal anti-inflammatory drugs (NSAIDS) (if taken) must be at a stable dose for at least one month prior to screening.
- •10. In general good health other than RA.
- •11. Use a medically reliable method of contraception throughout the study.
- •12. Provide written informed consent.
排除标准
- •1. Diagnosed with juvenile RA. 2. History of allergic or anaphylatic reactions to Cpn10. 3. Treatment with any DMARD other than stable doses of hydroxchloroquine, sulphasalazine, leflunomide, azothioprine, minocycline, gold or methotrexate within 3 months of screening. 4. prior treatment with more than one biological agent for RA. 5. Treatment with a small molecule investigational product within 28 days prior to screening or 5 times the half-life of the drug (whichever is longer) prior to day 0. 6. administration of intra-articular or parenteral glucocorticoids within 4 weeks of screening. 7. Dose of NSAID higher than the maximum recommended dose in the product information. 8. Current use of narcotic analgesics other than codeine or dextropropoxyphene at screening. 9. Active or latent bacterial, fungal, viral or atypical mycobacterial infections. 10. History of opportunistic infections (systemic fungal infections, parasites) within the past 6 months. 11. History of malignancy within the past 5 years (other than basal or squamous cell carcinoma or adequately treated carcinoma of the cervix). 12. Any live (attenuated) or killed virus or bacterial vaccines within 14 days of day 0. 13. Clinical evidence of hepatic insufficiency, liver cirrhosis or fibrosis. 14. History of viral hepatitis within 1 year prior to screening or history of drug-induced liver injury at any time prior to screening. 15. History of substance abuse within the last 5 years. 16. Female who is lactating or pregnant. 17. Seropositive test to HIV, Hepatitis B or Hepatitis C at screening. 18. White cell count < 3.2 x10^9/L. 19. Platelet count < 125 x 10^9/L. 20. Haemoglobin < 85 g/L. 21. Aspartate transaminase (AST), Alanine transaminase (ALT), Alkalline phosphatase (ALP) or serum creatinine > 2 times the upper limit of the normal range. 22. History of active tuberculosis confirmed by a chest x-ray and Quantiferon TB Gold test at screening. 23. Treatment with a biological agent for RA within 3 months of day 0. 24. Vaccines or allergy desensitisation therapy within 14 days of day 0. 25. Significant concurrent medical conditions which the investigator believes places the subject at an unaccceptable risk for participation in the trial.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the effects of a product, fibrinogen concentrate, to assist with rapid clotting of the blood, in patients with major bleeding caused by trauma.Trauma patients whereby the local major haemorrhage protocol has been activatedMedDRA version: 18.0 Level: LLT Classification code 10044461 Term: Trauma System Organ Class: 100000004863EUCTR2015-000875-28-GBHS Blood & Transplant48
进行中（未招募）
不适用
A multi-centre, randomised, double blind, placebo-controlled, parallel group, single dose, pilot study of the efficacy of 0.6 mg Amylmetacresol BP (AMC) and 1.2mg 2,4-Dichlorobenzyl alcohol (DCBA) throat lozenges in the relief of sore throat due to upper respiratory tract infection. - 0.6 mg AMC and 1.2 mg DCBA Lozenges Pilot Efficacy StudySore throatMedDRA version: 9.1Level: LLTClassification code 10041367Term: Sore throatEUCTR2008-005059-67-GBReckitt Benckiser Healthcare UK Ltd
已完成
2 期
A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren*s DiseaseNL-OMON47684niversity of Oxford, Research Services, Clinical Trials and Research Governance, Joint Research Office, Boundary Brook House35
进行中（未招募）
1 期
Repurposing anti-TNF for treating Dupuytren’s disease.EUCTR2015-001780-40-GBniversity of Oxford, Clinical Trials and Research Governance228
进行中（未招募）
不适用
A multi-centre, randomised, double-blind, placebo-controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven®) in the treatment of post-operative bleeding in patients following cardiac surgery requiring cardiopulmonary bypassheart disease/cardiac surgeryMedDRA version: 6.1Level: PTClassification code 10061026EUCTR2004-000100-40-GBovo Nordisk A/S5,000